Iris Bigalke
Papers
1
Total Citations
30
H-Index
1
About
Iris Bigalke is a pioneering translational researcher in cancer immunotherapy, with a primary focus on dendritic cell (DC) vaccines for high-risk prostate cancer. Her landmark long-term Phase I/II study, published in 2021, demonstrated the safety and feasibility of a personalized adjuvant DC vaccine administered after robotic radical prostatectomy, aiming to reduce biochemical relapse in patients with aggressive disease. This first-in-man trial, which has garnered 30 citations, represents a critical step toward preventing recurrence in noncurative prostate cancer by harnessing the patient’s own immune system. Bigalke’s work bridges surgical oncology and cellular immunotherapy, offering a novel strategy to improve outcomes for high-risk patients who currently face limited options after surgery. Her contributions underscore the potential of personalized vaccines to shift the treatment paradigm from reactive management of relapse to proactive immune-based prevention. By integrating rigorous clinical trial design with cutting-edge immunology, Bigalke is advancing the frontier of adjuvant cancer therapy, making her a key figure in the quest for durable remission in prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1